NYSEAMERICAN:AMPE

Ampio Pharmaceuticals Stock Forecast, Price & News

$1.80

+0.02 (+1.12 %)

(As of 06/14/2021 12:00 AM ET)

Add

Compare

Today's Range

$1.77

▼

$1.83

50-Day Range

$0.84

▼

$2.76

52-Week Range

$0.45

▼

$2.98

Volume1.22 million shs

Average Volume2.73 million shs

Market Capitalization$352.24 million

P/E RatioN/A

Dividend YieldN/A

Beta1.82

30 days | 90 days | 365 days | Advanced Chart

Receive AMPE News and Ratings via Email

Sign-up to receive the latest news and ratings for Ampio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

About Ampio Pharmaceuticals

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunology-based therapies for the treatment of prevalent inflammatory conditions in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-016, an intravenous treatment that is in Phase I/II clinical trial for COVID-19 patients with respiratory illness; and AP-014, an inhaled treatment that is in Phase I clinical trial for COVID-19 induced respiratory distress. The company is headquartered in Englewood, Colorado.

Ampio Pharmaceuticals to Present at the 2021 International Society for Pharmaceutical Engineers Annual Meeting and Expo
June 14, 2021 | finance.yahoo.com

Ampio Pharmaceuticals to Participate in the Alliance Global Partners' Virtual Summer Healthcare Symposium
June 11, 2021 | finance.yahoo.com

Ampio Pharmaceuticals Receives Investigational Review Board Approval for its Phase I Long COVID-19 Trial (AP-018)
May 10, 2021 | finance.yahoo.com

EXCLUSIVE: Ampio Pharmaceuticals Approved For Clinical Study Of Lead Drug In Long-Term Respiratory COVID-19 Symptoms
May 10, 2021 | feeds.benzinga.com

Ampio Pharmaceuticals, Inc. Reports First Quarter 2021 Financial Results and Provides Business Update
May 5, 2021 | finance.yahoo.com

Ampio Pharma's Inhaled COVID-19 Treatment Shows 78% Improvement In All-Cause Mortality
April 27, 2021 | finance.yahoo.com

Ampio Pharmaceuticals Provides Updates on Clinical Programs for Ampion™ in Osteoarthritis and COVID-19
April 27, 2021 | finance.yahoo.com

Ampion™ Reduces All-cause Mortality in COVID-19 Respiratory Distress by Nearly 80%
April 27, 2021 | finance.yahoo.com

Ampio Pharmaceuticals, Inc. to Report Fiscal 2021 First Quarter Financial Results and Provide Corporate Business Update
April 21, 2021 | finance.yahoo.com

Research Shows Ampion™ Gene Regulation Mimics the Anti-Inflammatory Effects of Steroids, but without Adverse Effects
April 19, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNYSEAMERICAN:AMPE
Previous SymbolNYSE:AMPE
CUSIP03209T10
CIK1411906
Webampiopharma.com
Phone(720) 437-6500
Employees18
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.09 per share
Price / Book20.00

Profitability

EPS (Most Recent Fiscal Year)($0.09)
Net Income$-15,890,000.00
Net MarginsN/A
Return on Equity-112.02%
Return on Assets-79.90%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares195,689,000
Market Cap$352.24 million
Next Earnings Date7/30/2021 (Estimated)
OptionableOptionable

MarketRank^™

Overall MarketRank^™

1.20 out of 5 stars

Medical Sector

957th out of 2,100 stocks

Pharmaceutical Preparations Industry

471st out of 831 stocks

3.5 Analyst's Opinion

Consensus Rating
Ampio Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.00, Ampio Pharmaceuticals has a forecasted upside of 122.2% from its current price of $1.80.
Amount of Analyst Coverage
Ampio Pharmaceuticals has received no research coverage in the past 90 days.

2.5 Community Rank

Outperform Votes
Ampio Pharmaceuticals has received 161 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Ampio Pharmaceuticals has received 164 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Ampio Pharmaceuticals has received 50.46% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Ampio Pharmaceuticals and other stocks. Vote “Outperform” if you believe AMPE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AMPE will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Ampio Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Ampio Pharmaceuticals does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Ampio Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $333,038.00 in company stock.
Percentage Held by Insiders
Only 3.60% of the stock of Ampio Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 15.82% of the stock of Ampio Pharmaceuticals is held by institutions.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Ampio Pharmaceuticals are expected to remain at ($0.08) per share in the coming year.
Price to Earnings Ratio vs. the Market
The P/E ratio of Ampio Pharmaceuticals is -22.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Ampio Pharmaceuticals is -22.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Ampio Pharmaceuticals has a P/B Ratio of 20.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) Frequently Asked Questions

Is Ampio Pharmaceuticals a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ampio Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Ampio Pharmaceuticals stock.
View analyst ratings for Ampio Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Ampio Pharmaceuticals?

Wall Street analysts have given Ampio Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Ampio Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Ampio Pharmaceuticals' next earnings date?

Ampio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, July 30th 2021.
View our earnings forecast for Ampio Pharmaceuticals.

How were Ampio Pharmaceuticals' earnings last quarter?

Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE) announced its earnings results on Tuesday, May, 4th. The specialty pharmaceutical company reported ($0.02) EPS for the quarter, meeting the consensus estimate of ($0.02).
View Ampio Pharmaceuticals' earnings history.

How has Ampio Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Ampio Pharmaceuticals' stock was trading at $0.5307 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AMPE stock has increased by 239.2% and is now trading at $1.80.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for AMPE?

1 brokers have issued 12-month price targets for Ampio Pharmaceuticals' stock. Their forecasts range from $4.00 to $4.00. On average, they anticipate Ampio Pharmaceuticals' stock price to reach $4.00 in the next year. This suggests a possible upside of 122.2% from the stock's current price.
View analysts' price targets for Ampio Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Ampio Pharmaceuticals' key executives?

Ampio Pharmaceuticals' management team includes the following people:

Mr. Michael E. Macaluso, Founder, Chairman & CEO (Age 69, Pay $457.04k)
Mr. Daniel G. Stokely CPA, CPA, CFO, Corp. Sec. & Treasurer (Age 57, Pay $419.5k)
Ms. Holli Cherevka, Chief Operating Officer (Age 38, Pay $288.04k)
Lane Hapke, VP of Manufacturing Operations
April Ramirez, Clinical Trial Mang.
Laura Goldberg, VP of Quality and Regulatory Operations

Who are some of Ampio Pharmaceuticals' key competitors?

Some companies that are related to Ampio Pharmaceuticals include Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly and (LLY), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT) and Supernus Pharmaceuticals (SUPN).
View all of AMPE's competitors.

What other stocks do shareholders of Ampio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ampio Pharmaceuticals investors own include Trevena (TRVN), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), Bionano Genomics (BNGO), Rigel Pharmaceuticals (RIGL), Cogent Biosciences (UMRX), ADMA Biologics (ADMA), Great Panther Mining (GPL), Zosano Pharma (ZSAN) and Miragen Therapeutics (MGEN).

What is Ampio Pharmaceuticals' stock symbol?

Ampio Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "AMPE."

Who are Ampio Pharmaceuticals' major shareholders?

Ampio Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (1.82%), Millennium Management LLC (0.98%), Geode Capital Management LLC (0.73%), HRT Financial LP (0.25%), Brighton Jones LLC (0.19%) and Northern Trust Corp (0.18%). Company insiders that own Ampio Pharmaceuticals stock include Dan Stokely, Holli Cherevka and Philip H Coelho.
View institutional ownership trends for Ampio Pharmaceuticals.

Which major investors are selling Ampio Pharmaceuticals stock?

AMPE stock was sold by a variety of institutional investors in the last quarter, including Jane Street Group LLC, Traynor Capital Management Inc., Price T Rowe Associates Inc. MD, Brighton Jones LLC, Bank of New York Mellon Corp, and HighPoint Advisor Group LLC. Company insiders that have sold Ampio Pharmaceuticals company stock in the last year include Dan Stokely, Holli Cherevka, and Philip H Coelho.
View insider buying and selling activity for Ampio Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying Ampio Pharmaceuticals stock?

AMPE stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, HRT Financial LP, BlackRock Inc., Goldman Sachs Group Inc., Geode Capital Management LLC, Cubist Systematic Strategies LLC, Chicago Capital LLC, and Captrust Financial Advisors.
View insider buying and selling activity for Ampio Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Ampio Pharmaceuticals?

Shares of AMPE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ampio Pharmaceuticals' stock price today?

One share of AMPE stock can currently be purchased for approximately $1.80.

How much money does Ampio Pharmaceuticals make?

Ampio Pharmaceuticals has a market capitalization of $352.24 million. The specialty pharmaceutical company earns $-15,890,000.00 in net income (profit) each year or ($0.09) on an earnings per share basis.

How many employees does Ampio Pharmaceuticals have?

Ampio Pharmaceuticals employs 18 workers across the globe.

What is Ampio Pharmaceuticals' official website?

The official website for Ampio Pharmaceuticals is ampiopharma.com.

Where are Ampio Pharmaceuticals' headquarters?

Ampio Pharmaceuticals is headquartered at 373 Inverness Pkwy Ste 200, ENGLEWOOD, CO 80112-5898, United States.

How can I contact Ampio Pharmaceuticals?

Ampio Pharmaceuticals' mailing address is 373 Inverness Pkwy Ste 200, ENGLEWOOD, CO 80112-5898, United States. The specialty pharmaceutical company can be reached via phone at (720) 437-6500.

This page was last updated on 6/14/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here